Role of mammalian target of rapamycin inhibitor in the treatment of metastatic epithelioid angiomyolipoma: A case report

International Journal of Urology

Volumn 20, Issue 9, 2013, Pages 938-941

  Kohno, Jin ^a   Matsui, Yoshiyuki ^a   Yamasaki, Toshinari ^a   Shibasaki, Noboru ^a   Kamba, Tomomi ^a   Yoshimura, Koji ^a   Sumiyoshi, Shinji ^a   Mikami, Yoshiki ^a   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Epithelioid angiomyolipoma; Everolimus; Mammalian target of rapamycin inhibitors; Targeted therapy; Tuberous sclerosis complex

Indexed keywords

C REACTIVE PROTEIN; EVEROLIMUS; MELAN A; MONOCLONAL ANTIBODY HMB 45; SUNITINIB; TEMSIROLIMUS;

ADULT; ANGIOMYOLIPOMA; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; EPITHELIOID ANGIOMYOLIPOMA; FEMALE; HUMAN; LIVER METASTASIS; LIVER RESECTION; LIVER TUMOR; LUNG TUMOR; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS TUMOR; PRIORITY JOURNAL; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

EPITHELIOID ANGIOMYOLIPOMA; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITORS; TARGETED THERAPY; TUBEROUS SCLEROSIS COMPLEX;

ANGIOMYOLIPOMA; FEMALE; HUMANS; KIDNEY NEOPLASMS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84883460726     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12095     Document Type: Article

References (10)

1. Nese N, Martingnoni G, Fletcher C etal. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: a clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am. J. Surg. Pathol. 2011; 35: 161-176.
2. Faraji H, Nguyen N, Mai K. Renal epithelioid angiomyolipoma: a study of six cases and a meta-analytic study. Development of criteria for screening the entity with prognostic significance. Histopathology 2009; 55: 525-534.
3. ") of the kidney: a case report and review of the literature. Am. J. Surg. Pathol. 2001; 25: 121-126.
4. Bissler J, McCormack F, Young L etal. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 2008; 358: 140-151.
5. US National Institutes of Health. Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangiomyomatosis (LAM) (EXIST-2). 2009. [Cited January 17, 2013.] Available from URL: http://clinicaltrials.gov/ct2/show/NCT00790400?term=exist-2&rank=1
6. Kenerson H, Folpe A, Takayama T, Yeung R. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum. Pathol. 2007; 38: 1361-1371.
7. Higa F, Uchihara T, Haranaga S etal. Malignant epithelioid angiomyolipoma in the kidney and liver of a patient with pulmonary lymphangioleiomyomatosis: lack of response to sirolimus. Intern. Med. 2009; 48: 1821-1825.
8. Wolff N, Kabbani W, Bradley T etal. Sirolimus and temsirolimus for epithelioid angiomyolipoma. J. Clin. Oncol. 2010; 28: e65-68.
9. Wagner A, Malinowska-Kolodziej I, Morgan J etal. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J. Clin. Oncol. 2010; 28: 835-840.
10. Shitara K, Yatabe Y, Mizota A etal. Dramatic tumor response to everolimus for malignant epithelioid angiomyolipoma. Jpn. J. Clin. Oncol. 2011; 41: 814-816.